Table 2.
Pertuzumab-based chemotherapy regimens as per the US Food and Drug Administration prescribing label (updated September 2013)
| Regimen | Dose and frequency |
|---|---|
| Neoadjuvant regimen | |
| FEC-THP* | 5-Flurouracil 600 mg/m2, concurrent with epirubicin 90 mg/m2, concurrent with cyclophosphamide 600 mg/m2, concurrent with every 3 weeks *3 cycles, followed by Docetaxel 75 mg/m2, concurrent with pertuzumab loading dose of 840 mg, followed by 420 mg, concurrent with trastuzumab 8 mg/kg loading dose, and then 6 mg/kg every 3 weeks *4 cycles, followed by trastuzumab alone 6 mg/kg every 3 weeks, to complete a total of 52 weeks of treatment |
| FECHP-THP* | 5-Flurouracil 600 mg/m2, concurrent with epirubicin 90 mg/m2, concurrent with cyclophosphamide 600 mg/m2, concurrent with pertuzumab loading dose of 840 mg, followed by 420 mg, concurrent with trastuzumab 8 mg/kg loading dose, and then 6 mg/kg every three weeks *3 cycles, followed by Docetaxel 75 mg/m2, concurrent with pertuzumab loading dose of 840 mg, followed by 420 mg, concurrent with trastuzumab 8 mg/kg loading dose, and then 6 mg/kg every 3 weeks *4 cycles, followed by trastuzumab alone 6 mg/kg every 3 weeks, to complete a total of 52 weeks of treatment |
| P-TCH | Pertuzumab loading dose of 840 mg, followed by 420 mg, concurrent with trastuzumab 8 mg/kg loading dose, and then 6 mg/kg, concurrent with docetaxel 75 mg/m2, concurrent with carboplatin AUC 6 every three weeks *6 cycles, followed by trastuzumab alone 2 mg/kg weekly or 6 mg/kg every 3 weeks, to complete a total of 52 weeks of treatment |
| Metastatic regimen | |
| Pertuzumab and trastuzumab | Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg, concurrent with pertuzumab loading dose of 840 mg, followed by 420 mg, concurrent with docetaxel 75–100 mg/m2 (at least 6 cycles) every 3 weeks |
Notes:
*
In the US, an Adriamycin–cyclophosphamide (AC) regimen is frequently used instead of an FEC regimen. However, there are no safety or efficacy data regarding the combination of an AC regimen with pertuzumab.
Abbreviation: AUC, area under curve.